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Abstract
Context: Neuromodulation is an expanding field of study for headache treatment to reduce pain by targeting structures within
the nervous system that are commonly involved in headache pathophysiology, such as the vagus nerve (VNS), occipital nerves, or
sphenopalatine ganglion (SPG) for stimulation. Pharmaceutical medical therapies for abortive and prophylactic treatment, such as
triptans, NSAIDs, beta-blockers, TCAs, and antiepileptics, are effective for some individuals, but the role that technology plays in in-
vestigating other therapeutic modalities is essential. Peripheral neuromodulation has gained popularity and FDA approval for use
in treating certain headaches and migraine headache conditions, particularly in those who are refractory to treatment. Early tri-
als found FDA approved neurostimulatory implant devices, including Cephaly and SpringTMS, improved patient-oriented outcomes
with reductions in headaches per month (frequency) and severity.
Evidence Acquisition: This was a narrative review. The sources for this review are as follows: Searching on PubMed, Google Scholar,
Medline, and ScienceDirect from 1990 - 2019 using keywords: Peripheral Neuromodulation, Headache, vagus nerve, occipital nerves,
sphenopalatine ganglion.
Results: The first noninvasive neurostimulator device approved for migraine treatment was the Cefaly device, an external trigemi-
nal nerve stimulation device (e-TNS) that transcutaneously excites the supratrochlear and supraorbital branches of the ophthalmic
nerve. The second noninvasive neurostimulation device receiving FDA approval was the single-pulse transcranial magnetic stim-
ulator, SpringTMS, positioned at the occiput to treat migraine with aura. GammaCore is a handheld transcutaneous vagal nerve
stimulator applied directly to the neck at home by the patient for treatment of cluster headache (CH) and migraine. Several other
devices are in development for the treatment of headaches and target headache evolution at different levels and inputs. The Scion
device is a caloric vestibular stimulator (CVS) which interfaces with the user through a set of small cones resting in the ear canal
on either side and held in place by modified over-ear headphones. The pulsante SPG Microstimulator is a patient-controlled device
implanted in the patient’s upper jaw via an hour-long oral procedure to target the sphenopalatine ganglion. The occipital nerve
stimulator (ONS) is an invasive neuromodulation device for headache treatment that consists of an implanted pulse generator on
the chest wall connected to a subcutaneous lead with 4 - 8 electrodes that is tunneled the occiput.
Conclusions: The aim of this review is to provide a comprehensive overview of the efficacy, preliminary outcomes, and limitations
of neurostimulatory implants available for use in the US and those pending further development.
Keywords: Peripheral Neuromodulation, Headache, Vagus Nerve, Occipital Nerves, Sphenopalatine Ganglion
1. Context
Headache is one of the leading causes of disability
and reduced productivity worldwide. Headache charac-
terizes nonspecific pain localized to the face and scalp
that can present in different forms (1). Migraines typi-
cally present as a debilitating class of headache – unilat-
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eral, pulsatile, and associated with nausea, vomiting, and
sensitivity to light and sound, lasting upwards of minutes
to hours. Some can present with prodromal aura, typ-
ically neurological manifestations such as visual distur-
bances with various individual triggers (2). The prevalence
of chronic daily headache internationally is 4%, with fe-
males reporting more than twice as often as males (3). The
American Journal of Medicine (AJM) reports lifetime preva-
lence of headache as 96%, with the most common classifi-
cations as tension-type headache and migraine, both more
commonly seen in women (3). In collaboration with the
nonprofit, WHO, Lifting the Burden, demonstrated that
headaches create a significant economic burden from de-
creased productivity, increased sick days, and disability
costs (4, 5). A recent health surveillance study conducted
by the CDC lists migraine and headache among top emer-
gent complaints, accounting for nearly 4 million ED visits
in the United States in 2014 (6, 7).
The main classifications of headache include migraine,
tension-type headache (TTH), cluster headache, and sec-
ondary causes of headache – either underlying systemic or
neurologic disease (2, 8). TTH is the most prevalent form
of headache, and nonspecific in comparison to migraine,
often presenting bilaterally without pulsatile features (2).
Cluster headache is among the least common, often idio-
pathic, unilateral, with occasional ocular pain and auto-
nomic symptoms (2). The pathophysiology of headache
is likely to be mediated by vasodilation of arteries and
cervical nerve root delivery of pain mediated signals. Re-
cent literature discusses the role of thalamo-cortical cir-
cuits in the premonitory stages of headache and the re-
lease of neuropeptide headache mediators such as calci-
tonin gene-related peptide (CGRP) and pituitary adenylate
cyclase-activating polypeptide (PACAP) (9). New therapies
include targeting the early signaling for prophylactic treat-
ment of headache and modulating neuropeptide levels for
pain management.
Abortive and prophylactic treatments of headache
constitute the mainstay of therapy for both migraine and
headache. Beta-blockers, TCAs, and antiepileptics are com-
mon evidence-based prophylactic medication while trip-
tans and NSAIDs function as abortive agents (9). Oc-
cipital nerve blocks and onabotulinim toxin A injections
are gaining popularity as non-pharmaceutical options
for chronic headache pain management and dietary and
lifestyle changes to avoid triggers. Behavioral therapy is an
important treatment modality that incorporates biofeed-
back and CBT for relaxation and pain modulation (10).
2. Evidence Acquisition
This was a narrative review. The sources for this review
are as follows: Searching on PubMed, Google Scholar, Med-
line, and ScienceDirect from 1990-2019 using keywords: Pe-
ripheral Neuromodulation, Headache, vagus nerve, occip-
ital nerves, sphenopalatine ganglion.
3. Results
3.1. Neuromodulation for Headaches
Neuromodulation is an expanding field of study for
headache treatment aimed at noninvasive therapy to re-
duce pain by targeting structures within the nervous sys-
tem commonly involved in headache pathophysiology,
such as the vagus nerve (VNS) or sphenopalatine ganglion
(SPG) for stimulation (11, 12).
3.1.1. Mechanism of Action
Neuromodulation combines biomedical engineering
and neurophysiology to optimize neuronal function and
aid in the treatment of pathological processes such as pain
and movement disorders. It is broadly defined as “the pro-
cess of inhibition, stimulation, modification, regulation or
therapeutic alteration of activity, electrically or chemically,
in the central, peripheral, or autonomic nervous systems”
(13). It can be divided into electrical and chemical modes
of delivery, where electrical provides stimulation to mus-
cles and nerves, and chemical often utilizes implants for lo-
cal delivery through epidural and intrathecal placements.
For its application to chronic pain, neuromodulation cap-
italizes on the gate control theory to provide relief in nar-
cotic refractory conditions by delivering a stimulus to den-
ervated or deafferented pain areas to help reprogram the
brain’s response to pain (14).
3.1.2. Indications
One of the main indications for neuromodulation
therapy is pain management. “[…] are used for a grow-
ing number of indications including pain (ischemic, vis-
ceral, and neurogenic), angina pectoris, peripheral vas-
cular disease, epilepsy, urinary disorders, spasticity from
spinal cord injury, cerebral palsy, or multiple sclerosis, and
diabetes” (15). Several advances in therapy include ONS
for chronic migraine relief and VNS for seizures and in-
tractable epilepsy refractory to surgery. Neuromodulation
is also considered in conditions refractory to other medi-
cal treatment and/or in conjunction with that treatment
to enhance pain control effects. However, there are some
limitations to its availability, due to access and cost, and its
rarity in usage as a standard treatment approach.
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3.1.3. Patient Selection
As pain is not a discriminatory pathology, any age or
gender can be affected and thus eligible for neuromodu-
lation for therapeutic management. The majority of mi-
graine sufferers are women, children, and patients who
have a familial prevalence. The intensity of migraines is
often individually elicited, but those particularly sensitive
to triggers and otherwise benign stimuli would benefit.
Those who suffer from chronic pain and chronic comor-
bidities would benefit the greatest, but use in terminal con-
ditions is potentially financially burdensome and would
require further quality measure workup. Due to the nature
of the device’s implantation, the patient would also have
to pass a pre-op evaluation and be a good surgical candi-
date. The treatment works best in enhancing existing re-
sponsiveness to conventional therapies, such as abortive
migraine therapy, but also in refractory cases. Another ma-
jor component in determining eligibility is psychological
attitude towards the treatment. There is the postulation
that the belief or willingness in the treatment to work dra-
matically affects outcomes and duration of relief (16, 17).
3.2. Currently Available Devices
3.2.1. Transcutaneous Supraorbital Neurostimulator
The first noninvasive neurostimulator device ap-
proved for migraine treatment was the Cefaly device. The
Cefaly device is an external trigeminal nerve stimulation
device (e-TNS) that transcutaneously excites the supra-
trochlear and supraorbital branches of the ophthalmic
nerve (V1) via a bipolar self-adhesive electrode (30 x 94
mm) applied to the forehead. The device is a constant
current generator with a maximum skin impedance of
2.2 kΩ. Rectangular biphasic symmetrical pulses zero are
delivered with a progressively increasing intensity from
1 to 16 mA over 14 minutes. Cefaly was the first medical
device FDA approved for migraine prophylaxis in 2014,
which has since been renamed Cefaly PREVENT. In 2017,
the Cefaly ACUTE device was released as an FDA approved
acute migraine therapy. The Cefaly DUAL device was also
released, which combines both acute and preventative
settings. Cefaly PREVENT requires daily, low-frequency,
short treatment sessions, whereas Cefaly ACUTE applies
a high-frequency, long treatment session. It is hypothe-
sized that the patient’s belief in or willingness toward the
success of the treatment can dramatically affect patient
outcomes and duration of migraine relief (18, 19).
Since 2008, clinical studies of the efficacy and mech-
anism of action of Cefaly have been performed. The PRE-
vention of Migraine using Cefaly (PREMICE) study was
the first prospective, multicenter, randomized, and sham-
controlled trial of the device (20). Published in 2013, the
PREMICE study found a greater therapeutic gain of eTNS
compared to pooled results of placebo-controlled trials
of topiramate (26.1% vs. 23.5%). Although topiramate is
more effective than eTNS in reducing migraine days, the
safety:efficacy ratio of Cefaly is superior. A follow-up sur-
vey of 2,313 headache patients who underwent a 40-day
trial of Cefaly found it to be safe and well-tolerated, with
only 4.3% of subjects reporting adverse events (21). The ad-
verse events reported with the Cefaly were all minor and
reversible, like forehead paresthesia (20). Trials of topira-
mate had 25% of patients stop therapy due to more sig-
nificant intolerable side effects, including fatigue, insom-
nia, and nausea (22). Since Cefaly does not have as wide-
ranging and severe side effect profile, eTNS is an attrac-
tive option for patients unwilling or unable to use anti-
migraine drugs.
A subsequent smaller study (n = 24) demonstrated ef-
ficacy of brief, high-frequency Cefaly treatment in patients
who had never used preventative medications, suggesting
Cefaly could be a first line treatment for low-frequency mi-
graineurs (23). A 2017 study found Cefaly to be effective in
reducing number of migraine days, intensity, and acute
medication use in both chronic and episodic migraine in
topiramate-refractory migraineurs (24). In an open-label
study of Cefaly used as an acute treatment in chronic mi-
graine with or without medication overuse disorder, treat-
ment was found to reduce pain and medication consump-
tion (25). These studies did not demonstrate significant
differences in pain relief between migraine type or the
presence of medication overuse. A separate prospective,
non-randomized study showed similar efficacy of Cefaly in
other types of primary headache (26). The ability of Cefaly
to improve patient outcomes in a clinically heterogeneous
patient population reflects the versatility of eTNS.
An open-labeled pilot trial evaluating Cefaly as an
acute migraine treatment showed an average reduction of
headache pain severity by 57.1% after a 1-hour e-TNS treat-
ment, with 76.7% of patients reporting ≥ 50% pain relief
(27). This prompted a randomized, double-blind, sham-
controlled trial: the ACME study (ACute treatment of Mi-
graine with External trigeminal nerve stimulation). The re-
sults showed e-TNS during a migraine attack caused a sig-
nificant reduction in mean headache intensity at multiple
time points than sham treatment (28).
Cefaly represents an FDA-approved option for both
acute and preventive treatment that can safely be used as
monotherapy or in combination with medication. How-
ever, it is important to consider the limitations of the avail-
able studies. Shortcomings of the clinical trials to date in-
clude clinical heterogeneity of migraine type, duration of
illness, and medication usage. Each study addressed the
differences present in their patient populations and per-
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formed subgroup analyses, which found these differences
did not significantly affect outcomes. The headache lo-
cation was not considered, which may be worth investi-
gating due to the variability between migraineurs. Com-
pliance has been less in Cefaly trials compared to drugs.
One study reported 40% of patients used it the appropriate
amount of time, and 4.4% did not use it all (21). However,
the satisfaction rate was 53.4% and reached 70.6% in the
PREMICE trial (20). More extensive randomized-controlled
trials (RCT) are necessary to fully define the versatility of
Cefaly eTNS application in migraine treatment.
3.2.2. SpringTMS
The second noninvasive neurostimulation device re-
ceiving FDA approval was the single-pulse transcranial
magnetic stimulator, SpringTMS (sTMS). The 1.5 kg hand-
held device (81 mm; W: 220 mm; D: 134 mm) is positioned
on the occiput and the patient presses a button to deliver
a single magnetic pulse of 0.9 T. The electrical current gen-
erated causes electromagnetic induction of neurons over
the target area of the device. Pre-clinical models have inves-
tigated the mechanism of action of transcranial magnetic
stimulation and suggest modulation of thalamocortical
signaling, opioidergic activity, and suppression of corti-
cal spreading depression are the primary mechanisms (29,
30). First approved in 2014 for acute migraine with aura
treatment, sTMS indications have since expanded to in-
clude acute and preventative treatment of migraine with
or without aura.
The first randomized, sham-controlled trial of sTMS
demonstrated pain relief at 2 h post-sTMS treatment com-
pared with sham stimulation and sustained relief at 24
h and 48 h after treatment (31). After introducing the
SpringTMS device in the UK, a post-market pilot program
demonstrated a possible preventative benefit for migraine
with and without aura, prompting further investigation
by the eNeura SpringTMS Post-Market Observational U.S.
Study of Migraine (ESPOUSE) (32, 33). The preventive treat-
ment included the delivery of four pulses twice daily, and
the acute treatment was a maximum of three treatments
of three pulses per attack. ESPOUSE was a multicenter,
prospective, open label observational study that had pa-
tients undergo three months of preventative and acute mi-
graine treatment. The ESPOUSE study demonstrated sim-
ilar outcomes compared to the post-market UK observa-
tional data with a 50% reduction in headache days in 46%
and 47% of patients. These outcomes were achieved in dif-
ferent populations (US versus UK) with different investiga-
tors indicating the consistency of sTMS efficacy. Both stud-
ies found sTMS to be well-tolerated with a mild side effect
profile. The most common side effect reported was light
headedness.
TMS’s safety has been well-established as it has been
used for decades diagnostically and therapeutically for a
range of neurological and psychiatric disorders (34). In
2017, the FDA approved sTMS for acute and preventative mi-
graine treatment and expanded clearance to children 12
years of age and older based on the demonstrated safety
profile and efficacy in the EPOUSE study and a pilot open-
label study in adolescents (35). The adolescent study did
not show a significant reduction in acute medication use
nor in moderate/severe pain days in the paired analysis.
Still, it did show 4.5 fewer headache days per month.
Contraindications to sTMS include the presence of
other signaling devices like cardiac pacemakers or metal
implants. Limitations of published studies to date on
sTMS are similar to those of eTNS, including clinical het-
erogeneity and small sample sizes. The greatest limita-
tion to ESPOUSE is the lack of a sham control. Success-
ful sham-controlled studies exist for tSNS and in the sTMS
study for acute migraine treatment (20, 28). The authors
of ESPOUSE explain creating a true sham for a preventive
treatment, which requires multiple treatments per day,
makes maintaining blinding difficult. An additional lim-
itation to ESPOUSE is the lack of subgroup analyses to ac-
count for differences of migraine type (episodic/chronic
and with/without aura) (33). No published studies exist
for sTMS in medication overuse or comparison to common
anti-migraine drug therapy like topiramate, unlike eTNS
literature (24). Due to the demonstrated efficacy in mi-
graine treatment and favorable safety profile, sTMS rep-
resents a well-tolerated, noninvasive, non-pharmacologic
migraine therapy. Similar to the evidence for eTNS, more
rigorous randomized controlled trials are needed to eluci-
date the efficacy across the heterogenous migraineur pop-
ulation and long-term safety of sTMS.
3.2.3. GammaCore
GammaCore is a handheld transcutaneous vagal nerve
stimulator applied directly to the neck at home by the pa-
tient for treatment of cluster headache (CH) and migraine.
The device is programmed for two-minute electrical stim-
ulation cycles and can be used at the onset of an attack or
prophylaxis. The initial iteration of the gammacore device
contained a charge for 300 treatment cycles, after which a
new device had to be purchased. The newer device comes
with a programmable card that reloads charges onto the
device (36). To deploy the device, the user applies gel to
the stimulation tips, locates their carotid pulse on either
side of their neck, and depresses the device directly over
that site. A slight downward tug of the user’s ipsilateral lip
typically indicates target intensity, which is modulated by
a wheel on the side of the device (37).
The cervical branch of the vagus nerve is the target area
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for treatment (38). Inputs from the vagus nerve connect
to various higher levels in the brain, and inhibiting affer-
ents into the caudal trigeminal nucleus. The trigeminal-
autonomic reflex pathway connects the autonomic affer-
ents of the vagus to the nerve to the pain locus at the
trigeminal nerve.
The Acute Treatment of Cluster Headache study, ACT1
and ACT2, found that gammacore as an adjunct to stan-
dard of care (SoC) treatment was superior to SoC alone in
episodic cluster headache. A cost analysis using a one-year
time horizon found an approximately $500 cost savings for
gammacore plus SoC versus SoC alone. Quality of life gains
were seen in addition to the cost savings and increased ef-
ficacy (39).
The PREVention and acute treatment of chronic clus-
ter headache (PREVA) study demonstrated a quality of life
gains in addition to cost savings and increased efficacy in
chronic cluster headache. Gammacore, approved by the
FDA in April 2017, is currently subject to reimbursement
policies on par with invasive implanted vagus nerve stim-
ulator devices. Ultimately, leading to a scenario where de-
vice acquisition is difficult for patients (40).
Current CH SoC has many drawbacks. Triptan overuse
in cCH is common, and high flow oxygen is logistically im-
practical. Difficulties with high flow oxygen include re-
imbursement, portability and fire hazard, and is imprac-
tical except for nocturnal attacks. Suboccipital corticos-
teroid injections, also viewed as fairly standard treatment,
are subject to many drawbacks as well. This includes treat-
ment by a professional at a medical setting and long-term
effects such as Cushing syndrome, blood glucose elevation,
and increased risk for avascular necrosis of the femoral
head. Prophylactic medications such as verapamil and
lithium maintain high levels of safety and tolerability is-
sues (3).
GammaCore is not as widely studied in migraine, how-
ever, initial results have proven promising. A study evalu-
ating acute migraine treatment in adolescents found that
46.8% (22/47) did not need rescue medications when using
the gammacore device, and treatment was well tolerated
(41).
The vagus nerve is a major parasympathetic branch
of the autonomic nervous system. Eighty percent of the
nerves are afferent projections to the nucleus tractus soli-
tarius (NTS) of the brainstem. The vagus nerve has been a
treatment target for over 20 years in epilepsy with iVNS de-
vices. Another stimulator, Nemos, has attempted to target
the vagus nerve at its auricular branch at the concha of the
ear. Transcutaneous stimulation was postulated to require
too much current to alter A and B fibers and thought to be
too big of a hurdle to provide pain modulating treatment.
The energy produced by gammaCore is pulsed to produce
an alternating sine wave current, allowing for fifteen times
greater energy transfer compared to implantable models,
all while eliciting minimal nociceptive pain (42).
3.3. Non-FDA Approved Devices
3.3.1. The Scion Device (Caloric Vestibular Stimulator)
Several other devices are in development to treat
headache and target headache evolution at different levels
and inputs. The Scion device is a caloric vestibular stimu-
lator (CVS) used for 20 minutes once or twice a day. The de-
vice interfaces with the user through a set of small cones
resting in the ear canal on either side and held in place by
modified over-ear headphones. An element with the device
heats and cools the cones causing an alteration in vestibu-
lar nerve conduction (43).
Standard CVS employs water or air and is difficult for
home use. The Scion Device employs a solid-state element
to create thermal waveforms. Thermal variation causes
density changes in endolymphatic fluid. CVS affects the
brainstem pacing center autoregulatory center and initi-
ates the vestibulo-ocular reflex, causing horizontal nystag-
mus. Additionally, CVS alters cerebral blood flow velocity.
Migraine etiology involves cerebral blood flow dysregula-
tion and brainstem dysfunction. The Scion Device seeks to
modify these two aspects of migraine pathology. A small
pilot project attempted to evaluate the feasibility of at-
home use. Three migraineurs who participated in the trial
all reported a decreased number of headaches (44).
A subset of the migraine population features vertigi-
nous symptoms during attacks increasing interest in the
role that vestibular inputs may play in migraine pathol-
ogy. In the U.K., a larger study at the University of Kent had
81 volunteers with episodic migraine, using a protocol of
CVS for 2 minutes every day over a three-month timespan.
The study saw decreased frequency and severity during the
trial (45).
An additional trial is currently ongoing and hopes to
use a CVS device for thermoneuromodulation to treat sub-
stance abuse disorder. It is an interventional, randomized,
single-blind, sham-controlled study with 24 participants
at Wake Forest Medical Center. Participants receive CVS or
sham therapy twice daily over five days. Trial participants
receive pre and post mood and substance use question-
naires, in addition to structural and functional MRI and
urine drug screens (46).
3.3.2. Sphenopalatine Ganglion (SPG) Stimulator Pulsante
The sphenopalatine ganglion (SPG) has long been a tar-
get for headache treatment. The pulsante SPG Microstim-
ulator is a device implanted in the upper jaw via an hour-
long oral procedure. The microstimulator is controlled by
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a patient-controlled handheld remote and features no bat-
tery. The device is powered by induction via radiowaves
emitted by the handheld device. Initial studies have re-
duced episodic clusters in 85 patients by 68% concern-
ing frequency and intensity. A lead of the stimulator is
placed into the pterygopalatine fossa under CT guidance
to ensure proper midface location. The Pathway CH-1 and
Pathway R-1 studies have sought to evaluate the efficacy of
sphenopalatine ganglion stimulation in the treatment of
99 patients with cluster headache.
Thirty-three patients in the Pathway CH-1 over 24
months saw a 50% or greater acute effectiveness or 50% or
greater reduction in frequency. In total, 5961 attacks were
recorded. Forty-five percent of participants were acute re-
sponders, with 78% of those patients employing stimula-
tor monotherapy. Additionally, 33% saw a decrease in the
frequency of attacks. In total, 61% (20/33) saw a reduction
in intensity, frequency, or both. The majority of partici-
pants saw maintained benefits throughout the 24-month
study. SPG stimulation seeks to treat a cohort of mostly dis-
abled patients who have seen high treatment failure rates
with medication that can be both challenging to tolerated
and inconvenient. Sham control in the CH-1 trial lowers the
likelihood of treatment benefit due to surgical response of
implanting the device itself.
Thirty percent improvement is typically used as a
threshold for tension, headache, and migraine. Since cCH
is so debilitating, evaluating cCH treatment with such a
threshold may be reasonable. When evaluating with a
thirty percent improvement threshold, eighty percent of
participants found benefit with treatment. Over the 24
months, 2 of 33 participants are no longer having attacks,
effectively converting from cCH to eCH. During the trial,
some concern was raised over increased contralateral at-
tacks; however, half of the 11 patients experiencing con-
tralateral attacks had a prior history (47).
Using data from the Pathway R-1 Registry, a 1-year cost
analysis was performed and a significant cost savings of
approximately 41-51% was seen using German medication
prices in 2016. Acute medication savings contribute to 97%
of that cost savings (48).
Paresthesia and pain in the maxillary area were the
primary side effects seen related to the device’s place-
ment. These side-effects decreased significantly over sev-
eral months, yet the positive effects have remained over
time in longer-term studies (49). Trials employing a tempo-
rary electrode placed in the pterygopalatine fossa for mi-
graine attacks appear less promising (50).
Smaller trials with seven patients using trigeminal or
SPG stimulation with or without peripheral stimulation
and temporary lead placement via lateral transpterygoid
are being performed. Trigeminal stimulation via subtem-
poral craniotomy to meckel’s cave limits V3 involvement
and masseter contraction as opposed to the Hartel ap-
proach (51).
A small trial of 59 participants with cCH were im-
planted with bilateral SPG and continuous stimulation.
Some saw daily to less than one per week attacks and dis-
continued previous medication regime (52). A high fre-
quency of 120 hz or greater is thought to cause depletion
of neurotransmitters in efferent parasympathetic nerves.
Stimulation of the peripheral autonomic ganglion could
affect a centrally mediated disorder via feedback mecha-
nisms or depletion of parasympathetic NTs (53).
The SPG is a peripheral bundle of nerves containing
autonomic, sensory, and motor neurons located in an in-
verted 2cm by 1cm pyramid-shaped space posterior to the
nasal cavity. This specific collection of nerves is implicated
in a diverse range of processes that, when dysfunctional,
are implicated in headache generation. The SPG simula-
tion allows for modulation of neurogenic inflammatory
pathways, the trigeminovascular system, and the parasym-
pathetic system (54). Neuromodulation holds a distinct
advantage with its ability to be flexible and reversible.
3.3.3. Occipital Nerve Stimulator
An invasive neuromodulatory device for headache
treatment that has been investigated is the occipital nerve
stimulator (ONS). The device consists of an implanted
pulse generator on the chest wall connected to a subcuta-
neous lead with 4-8 electrodes that is tunneled the occiput.
The patient applies stimuli with a handheld remote con-
trol. Before permanent implantation, neurostimulation is
trialed for up to two weeks. If greater than 50% pain reduc-
tion is achieved, a permanent implantation may be pur-
sued. The mechanism of action of ONS is incompletely un-
derstood but is suggested to be a combination of periph-
eral and central neuromodulation (55, 56).
The efficacy of ONS has been studied in the prevention
of medication-refractory cluster headache and migraine.
Randomized, sham-controlled trials have evaluated ONS
over a 3-month treatment period. The ONSTIM study re-
ported a 39% responder rate in the ONS treatment group,
which is comparable to topiramate’s response rate (57). De-
spite the limitations of this study, including a short obser-
vation period and possible unblinding of the preset stim-
ulation group, the authors concluded that ONS was rela-
tively safe and warranted further study.
A larger-scale randomized, sham-controlled study did
not achieve the primary outcome of at least 50% pain
reduction at three months. Still, it did achieve sec-
ondary endpoints (30% reduction in pain scores, number
of headache days, and migraine-related disability) (58). Ad-
verse events related to the device in these two studies were
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not uncommon, including lead migration and infection
with some patients requiring hospitalization or surgical
intervention. The PRISM study was the third multicenter
study, published only in abstract form, which found no sig-
nificant difference in the primary end point of the num-
ber of migraine days per month between the randomized
ONS and sham groups (59). A recent long-term prospec-
tive study of ONS in refractory chronic migraine patients
with a 7-year follow-up period found substantial pain re-
duction (VAS -4.9 ± 2.0 points) in ONS patients (60). Com-
plete resolution of attacks by the final follow-up visit was
achieved in 5/35 patients. Although limited by the uncon-
trolled and open-label study design, these results suggest
a sustainable benefit in refractory chronic migraine.
Initial open-label studies in medication refractory
chronic cluster headache patients showed improvement
with ONS (61, 62). Recent open-label studies of ONS in re-
fractory chronic cluster headache have found ONS to main-
tain safety and efficacy over the long-term. One study with
a follow-up period of six years had 66% of patients achieve
at least a 50% reduction in headaches per day. One-third
were non-responders, and half of these patients had pre-
viously been responders before developing tolerance (63).
Another study with a mean follow-up period of 39 months
had a response rate of 52.9% and a 62% drop in triptan us-
age (64). ONS also improved functional and emotional im-
provements measured by HIT-6, MIDAS, and HAD scales in
a prospective observational study (65).
Investigation of ONS for application in occipital neu-
ralgia is limited to case series. In a recent retrospective re-
view, ONS’s success rate was 85%, with a significant reduc-
tion in pain score (66). Another long-term study of ONS in
intractable chronic unilateral neuralgiform headache had
a 77% response rate (at least 50% reduction in daily attack
frequency) with reduction in attack severity and duration
(67).
Unlike noninvasive neurostimulator devices, ONS is
not FDA approved and incurs greater out-of-pocket costs.
Due to the prohibitive cost and potential adverse events
with invasive ONS, this treatment modality is recom-
mended to be reserved for only the most severely af-
fected refractory headache patients. The limited number
of randomized-controlled trials and heterogeneity of out-
come measures between studies offers a low to moderate
level of evidence for ONS, but the demonstrated ability to
affect positive change in the most refractory headache pa-
tients warrants continued research.
4. Discussion
Neuromodulation is an expanding field of study for
headache treatment aimed at noninvasive therapy to re-
duce pain by targeting structures within the nervous sys-
tem commonly involved in headache pathophysiology,
such as the vagus nerve (VNS) or sphenopalatine ganglion
(SPG) for stimulation (11). The first noninvasive neurostim-
ulator device approved for migraine treatment was the
Cefaly device. The Cefaly device is an external trigeminal
nerve stimulation device (e-TNS) that transcutaneously ex-
cites the supratrochlear and supraorbital branches of the
ophthalmic nerve (V1) via a bipolar self-adhesive electrode
(30 x 94 mm) applied to the forehead. Larger randomized-
controlled trials (RCT) are necessary to fully define the ver-
satility of Cefaly eTNS application in migraine treatment.
The second noninvasive neurostimulation device receiv-
ing FDA approval was the single-pulse transcranial mag-
netic stimulator, SpringTMS (sTMS). Similar to the evidence
for eTNS, more rigorous randomized controlled trials are
needed to elucidate the efficacy across the heterogenous
migraineur population and long-term safety of sTMS. Gam-
maCore is a handheld transcutaneous vagal nerve stimula-
tor applied directly to the neck at home by the patient for
treatment of cluster headache (CH) and migraine. Gamma-
Core is not as widely studied in migraine, however, initial
results have proven promising.
Several other non-FDA-approved devices are in devel-
opment to treat headache and target headache evolution
at different levels and inputs. They require more research
in different age populations to be considered as prescribed
treatments. The Scion device is a caloric vestibular stimu-
lator (CVS) used for 20 minutes once or twice a day. The de-
vice interfaces with the user through a set of small cones
resting in the ear canal on either side and held in place by
modified over-ear headphones. The sphenopalatine gan-
glion (SPG) has long been a target for headache treatment.
The pulsante SPG Microstimulator is a device implanted in
the upper jaw via an hour-long oral procedure. And finally,
the occipital nerve stimulator (ONS). The device consists of
an implanted pulse generator on the chest wall connected
to a subcutaneous lead with 4-8 electrodes that is tunneled
the occiput.
4.1. Limitations of Therapy
While there have been promising initial results from
invasive and noninvasive neuromodulation devices for
headache, there is still much about the mechanism that is
unknown. Pending completion of further pilot trials, clin-
ical trials in controlled settings are required for many of
these devices to receive FDA approval for use in provider
settings as an abortive or prophylactic treatment beyond
refractory intervention. Transcranial magnetic stimula-
tion has been FDA approved for use in patients with mi-
graines with aura as abortive therapy and is now expand-
ing for approval in chronic migraines (19). The upfront cost
Anesth Pain Med. 2020; 10(6):e110515. 7
Urits I et al.
of interventional management is often offset in the long
term with reduced use of pharmaceutical agents; however,
most neuromodulatory procedures are indicated only in
refractory cases (36). Several studies aimed at improving
lead placement for ONS to reduce adverse events associ-
ated with lead migration post implantation; however, this
specialized technique can serve as a barrier to the ability
of providers to offer neuromodulation as a common ther-
apy (68). Further ongoing studies on neuromodulation are
investigating the specified targets and mechanisms of ac-
tion of treatment. Much of this updated technology is new,
and the long-term impact is not yet clear (69). Additional
limitations include surgical error, adverse events, individ-
ualized patient response to therapy, and patient user error.
5. Conclusions
Headache and migraine headache are well-established
diagnoses with a significant associated worldwide eco-
nomic burden to the patient and society. While pharma-
ceutical medical therapies for abortive and prophylactic
treatment, such as triptans, NSAIDs, beta-blockers, TCAs,
and antiepileptics, are effective for some individuals, the
role that technology plays in investigating other therapeu-
tic modalities is important. Peripheral neuromodulation
has gained popularity and FDA approval for use in the treat-
ment of certain headache and migraine headache condi-
tions, particularly in those who are refractory to treatment.
In this review, we examined the methodology, efficacy, pre-
liminary outcomes, and limitations of several clinical tri-
als of different neurostimulatory implants, including the
Cefaly Cranial Nerve Stimulator, SpringTMS, gammaCore,
Scion Device, SPG Stimulator Pulsante, and the ONS. Early
trials found FDA approved devices Cephaly and SpringTMS
to improve patient-oriented outcomes such as reductions
in headaches per month (frequency), and severity, but with
limitations in sample size and heterogeneity of study pop-
ulation.
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